News Lupin Limited NSE India S.E.

Equities

LUPIN

INE326A01037

Delayed NSE India S.E. Other stock markets 03:21:53 2024-05-10 am EDT			5-day change	1st Jan Change
1,600 ^INR	+1.02%		-3.25%	+21.02%

May. 09	Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	MT
May. 09	Lupin Limited Announces Board Appointments	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	May. 09	MT
Lupin : May 9, 2024 Jeffrey Kindler and Alfonso Zulueta Join Lupin Board as Independent Directors	May. 09	PU
Lupin Limited Announces Board Appointments	May. 09	CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold	May. 08	MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024	May. 07
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	May. 07	MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	May. 06	RE
Lupin : May 6, 2024 Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP	May. 06	PU
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 06	CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 06	CI
Lupin : May 3, 2024 Lupin Launches Rymti® Biosimilar Etanercept in Canada	May. 03	PU
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	Apr. 30	CI
Lupin : April 25, 2024 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%	Apr. 25	PU
Lupin : April 25, 2024 Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO	Apr. 25	PU
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	Apr. 23	MT
Lupin : April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility	Apr. 23	PU
Lupin : April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States	Apr. 22	PU
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	Apr. 22	RE
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	Apr. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lupin Limited NSE India S.E.

Equities

LUPIN

INE326A01037

Summary

Filters